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Introduction: With the incredibly high incidence of Type 2 Diabetes in the current population of 
emergency department patients, it is critical for clinicians to understand the possible complications of the 
treatment of this disease. Medication like canagliflozin are more common to encounter on patient’s home 
medication lists and clinicians should be aware of how these medications, alone or combined with dietary 
modifications, can result in significant pathology and even mortality if not appropriately treated.
Case Report: We report a case of a patient with type II diabetes mellitus who presented with 
euglycemic diabetic ketoacidosis in the setting of concurrent use of canagliflozin, a sodium-
glucose transporter-2 (SGLT-2) inhibitor, and strict adherence to a low-carbohydrate ketogenic diet 
for weight control. 
Discussion: Euglycemic ketoacidosis has previously been observed in both diabetic and non-
diabetic patients following strict ketogenic diets, as well as in diabetic patients being treated with 
SGLT-2 inhibitors. 
Conclusion: As more patients choose ketogenic diets for weight control and diabetes management, 
clinicians should be aware of this potentially life-threatening complication in patients concurrently 
taking SGLT-2 inhibitors. [Clin Pract Cases Emerg Med. 2020;4(2):185–188.]  
Keywords: SGLT-2 Inhibitors; Ketoacidosis; Low-carbohydrate; Ketogenic.
INTRODUCTION
Very low-carbohydrate, or ketogenic, diets originated in 
the realm of fad weight-loss diets, but the practice has moved 
into the armamentarium of medicine in controlling weight, 
epilepsy, and diabetes. Sodium-glucose transporter-2 (SGLT-2) 
inhibitors have also become more heavily used in the control of 
diabetes, leading to an increased incidence of concomitant use 
of ketogenic diets and SGLT-2 inhibitors to control weight in 
diabetic patients.1,2 Given that both ketogenic diet and SGLT-
2 inhibitors alone can result in euglycemic ketosis,3,4 there is 
likely an increased risk of developing this derangement when 
the diet and medication are combined. We report here the case 
of a patient who developed life-threatening euglycemic ketosis 
University of Nevada Las Vegas, Department of Emergency Medicine, Las Vegas, Nevada
while adhering to a strict ketogenic diet with concomitant 
canagliflozin use.
CASE REPORT
A 31-year-old female with a history of type II diabetes 
mellitus (T2DM) presented to a primary care office with 
dizziness and shortness of breath worsening over one week. 
She also noted slurring of her speech, nausea, pain radiating 
down the posterior aspect of both legs, and constipation. She 
had no history of previous episodes of diabetic ketoacidosis 
(DKA) or hyperosmolar hyperglycemic state (HHS). The 
patient had been attempting to control her T2DM by following 
a very low-carbohydrate, ketogenic diet for about two weeks, 
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What do we already know about this clinical 
entity? 
Euglycemic diabetic ketoacidosis (EDKA) and its 
relation to sodium-glucose transporter-2 (SLGT-2) 
inhibitors has been previously acknowledged and 
cases reported.
 
What makes this presentation of disease 
reportable? 
Our case represents a novel combination of 
extreme EDKA in a patient on an SLGT-2 inhibitor 
in combination with a very-low carbohydrate (or 
ketogenic) diet. 
What is the major learning point? 
Ketogenic diets and SGLT-2 inhibitor use, both 
singly and in combination, can lead to severe, life-
threatening EDKA.
How might this improve emergency medicine 
practice? 
Clinicians should consider EDKA in acidotic patients 
for whom new dietary trends can lead to significant 
medication interactions and morbidity.
during which she had restricted her carbohydrate intake to 10-
15 grams per day. Fluid intake included 3-4 liters of water per 
day and pickle juice. Over this time, she had a 12.2 kilogram 
weight loss. She had previously used long-acting insulin 
(insulin detemir) to control her glucose but had not needed to 
use insulin to maintain normoglycemia in weeks and was not 
using insulin at presentation. She stopped using insulin at the 
time of starting the ketogenic diet. 
At the time of presentation, her T2DM management regime 
consisted solely of canagliflozin and dietary modifications. The 
patient initially presented to her primary care physician, where 
she was found to have a blood glucose of 133 milligrams per 
deciliter (mg/dL) on fingerstick and positive urine ketones. 
She was sent to the emergency department (ED) for further 
evaluation. Initial vital signs in the ED were blood pressure 
126/78 millimeters of mercury, pulse 137 beats per minute, 
temperature 97.7º Fahrenheit (36.5º Celsius), respirations 24 
breaths per minute, and oxygen saturation 100% on room air. 
On physical exam, the patient appeared acutely ill. Neurological 
exam on presentation was notable for Glasgow Coma Scale of 
15, drunken affect, gait instability, and mildly slurred speech 
without aphasia. 
Initial electrocardiogram showed sinus tachycardia with 
normal intervals. Chest radiograph was normal. Laboratory 
evaluation showed a pH on a venous blood gas of 7.056 with 
a bicarbonate of 8.0 milliequivalents per liter (mEq/L), blood 
glucose of 139 mg/dL, blood ketones of 80 mg/dL, lactate 
of 1.4 millimole per liter (mmol/L), and an anion gap of 29. 
The remainder of lab results are displayed in the Table. The 
patient was treated with a bolus of one L of lactated Ringer’s 
solution, followed by an additional of one L 5% dextrose 
(D5) normal saline and an intravenous potassium bolus of 20 
mEq. After administration of approximately 200 milliliters of 
D5-containing solution, the patient had normalization of her 
neurological deficits, with no further speech slurring or feelings 
of intoxication. An insulin infusion was not started emergently, 
in order to facilitate transfer to an appropriate facility that could 
provide intensive care unit (ICU) admission and management.
The patient was transferred for admission to ICU level of 
care for severe metabolic acidosis, ketosis, and tachycardia. 
The patient had an uneventful course over the next few days 
with normalization of her ketones and acidosis while being 
treated with an insulin infusion with concomitant glucose-
containing fluids to maintain euglycemia. She was discharged 
at baseline health and was lost to follow-up.
DISCUSSION
This case demonstrates the occurrence of euglycemic 
ketoacidosis in a patient with T2DM concurrently following 
a low-carbohydrate, ketogenic diet and using an SGLT-2 
inhibitor. This is an uncommon cause of altered mental status, 
and it is important for emergency physicians to be aware of 
this potential complication of diabetes management. 
Canagliflozin is an oral sodium-glucose cotransporter-2 
(SGLT-2) inhibitor approved by the United States Food and 
Drug Administration (FDA) for treatment of T2DM and has 
been shown to improve glycemic control, weight loss, and 
hemoglobin A1c levels. SGLT-2 inhibitors decrease serum 
glucose concentrations by preventing glucose reabsorption 
in the proximal renal tubule of the kidney, thereby promoting 
glucosuria. SGLT-2 inhibitors also stimulate glucagon secretion 
from the alpha cells of the pancreas, minimizing the potential 
for hypoglycemic events. Although SGLT-2 inhibitors have 
shown efficacy in diabetes management, serious adverse events 
have been associated with their use. In 2017 the FDA initiated 
a boxed warning regarding the increased risk of leg and foot 
amputations in patients taking canagliflozin. Large surveillance 
studies have also noted increased risk of diabetic ketoacidosis 
with SGLT-2 inhibitors.4  
Euglycemic diabetic ketoacidosis (EDKA) is a 
previously rare clinical condition now showing increasing 
prevalence with the use of SGLT-2 inhibitors. The 
pathogenesis of EDKA involves an increased glucagon to 
insulin ratio, in which ketogenesis is stimulated without 
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hyperglycemia. Increased glucagon levels contribute to 
gluconeogenesis, glycogenolysis and fatty acid metabolism 
to mobilize energy substrates.5 In diabetic patients, however, 
the relative shortage of insulin precludes intracellular 
glucose utilization, further exacerbating metabolic acidosis. 
SGLT-2 inhibitors promote ketoacidosis by increasing 
glucagon secretion and limit available circulating glucose 
by promoting glucosuria. SGLT-2 inhibitors also exacerbate 
the osmotic diuresis of ketoacidosis. Normally, glucosuria 
occurs when blood glucose concentrations exceed 225 mg/
dL. SGLT-2 inhibitors block reabsorption of glucose in the 
proximal renal tubule even at physiologic serum glucose 
concentrations and cause glucosuria and osmotic diuresis 
even in normoglycemia. 
Low-carbohydrate, ketogenic diets significantly restrict the 
dietary supply of carbohydrates, promoting a ketogenic state 
of fatty acid metabolism. Although ketogenic diets induce a 
state of ketosis, they are not commonly associated with diabetic 
ketoacidosis.6,7 However, a previous case of ketoacidosis 
during a low-carbohydrate diet has been reported.8 Treatment 
for EDKA is not fundamentally different from the treatment 
of hyperglycemia DKA, using fluid resuscitation and insulin 
administration as the mainstays of therapy.9,10 However, patients 
will likely require earlier administration of glucose-containing 
fluids and should have the SGLT-2 inhibiting medication held. 
At discharge, consideration should be given to discontinuing the 
SGLT-2 inhibitor.
Since both low-carbohydrate, ketogenic diets and SGLT-
2 inhibitors increase glucagon secretion while limiting serum 
glucose levels, a synergistic effect increasing the risk for EDKA 
is plausible. Cases of severe ketoacidosis associated with a 
low-carbohydrate diet and use of ipragliflozin and dapagliflozin 
have previously been reported.11,12 Low-carbohydrate/high-fat 
meals stimulate glucagon production and fatty acid metabolism 
while limiting serum glucose availability. This physiologic state 
is likely exacerbated by the concurrent glucagon upregulation 
and depletion of serum glucose caused by SGLT-2 inhibitors, 
leading to severe acidosis with ketosis. The limited supply of 
dietary carbohydrates combined with SGLT-2 inhibitor-induced 
glucosuria may create a state of diabetic ketoacidosis without 
elevated serum glucose. This association will require further 
study for validation.
The patient’s initial altered mental status and speech 
changes may be attributable to her relative depletion of 
intracellular and intravascular glucose stores. Similar changes 
in mental status in patients with alcoholic ketoacidosis (AKA) 
have been previously attributed to intracellular hypoglycemia. 
As discussed above, this patient also experienced relative 
hypoglycemia due to her low relative insulin levels, creating 
a similar state as that of AKA.13 Thus, the treatment with 
the glucose-containing fluids likely terminated the patient’s 
neurologic symptoms by resolving her relative hypoglycemia.
CONCLUSION
Euglycemic diabetic ketoacidosis is a recognized 
complication of SGLT-2 inhibitor use for weight and 
glucose control in patients with diabetes. However, there 
have been few if any previous published cases that were 
complicated by a concomitant ketogenic diet. Our goal is 
not to defame the practice of using ketogenic diets in an 
effort to control body weight and blood glucose, but to 
caution clinicians that ketogenic diets and SGLT-2 inhibitor 
use, both singly and in combination, can lead to severe, 
life-threatening EDKA. 
Lab Value RR Units
Sodium 139 136-145 mEQ/L
Potassium 3.5 3.5-5.1 mEQ/L
Chloride 102 98-107 mEQ/L
Carbon 
Dioxide
8 22-30 mEQ/L
Anion Gap 29 3-11 NA
BUN 12 7-18 mg/dL
Creatinine 0.85 0.6-1.3 mg/dL
Glucose 139 70-99 mg/dL
Lactate 1.4 0.4-2.0 mMol/L
Serum 
Osmolality
295 280-295 mOSM/kg
Ammonia 27 <32 µMol/L
ß-Hcg NEG NA NA
Total Protein 8 6.4-8.2 g/dL
WBC 10.6 4-10 k/mm3
Hemoglobin 16.1 11-15 g/dL
Platelets 287 150-400 k/mm3
INR 0.8 NA NA
Urine Ketones 80 NEG mg/dL
Urine Glucose 500 NEG mg/dL
Urine Blood NEG NEG NA
Urine Protein 100 NEG mg/dL
RR, reference range; mEQ, milliequivalents; NA, not applicable; 
BUN, blood urea nitrogen; mg, milligrams; dL, deciliter; mMol, 
millimoles; L, liter; mOSM/kg, milliosmoles per kilogram; µMol, 
micromoles; ß-Hcg, human chorionic gonadatropin beta-subunit; 
NEG, negative; g, gram; WBC, white blood count; K/mm3, thousand 
per cubic millimeter; INR, international normalized range.
Table. Initial laboratory values of patient who presented to the 
emergency department with dizziness, shortness of breath, and 
slurred speech.
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